ASCO GI Conference Coverage
Filter News By:
There are no ASCO GI Conference Coverage articles to show.
News Commentary
There is no ASCO GI Conference Coverage commentary.

OBR Green
There are no ASCO GI Conference Coverage OBR Green articles.
Featured Videos
There are no ASCO GI Conference Coverage videos.
OBR Blog
There are no ASCO GI Conference Coverage blog entries.

OBR Tweets

Jan 15
Dean Gesme, MD: C-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play a significant role… https://t.co/FPThNu4aTT

Jan 14
Howard Sandler, MD, MS, FASTRO: Radiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit… https://t.co/pGbHsJJAbs

Jan 14
Tomasz M. Beer, MD: Hot flashes are a common consequence of hormonal therapy for prostate cancer and strategies to… https://t.co/owVbzC4Sex

Jan 13
William McGivney, PhD: In Oncology, drug/biologic development is clearly in a world of orphan diseases. The FDA def… https://t.co/LXXvSjOK2x

Jan 07
H. Jack West, MD: Perhaps a bit surprising for pembro, which has had the luck or efficacy to usually be just a shad… https://t.co/bTjrJlJQwv

Dec 23
Debu Tripathy, MD: Trastuzumab deruxtecan (Enhertu), a HER2-targeting antibody drug conjugate, will represent an im… https://t.co/1x3NMQ6ZkN

Dec 16
Gwen Nichols, MD, @DrGwenNichols of @LLSusa regarding the collaboration between the Leukemia and Lymphoma Society a… https://t.co/mhmBcEyIPo

Dec 16
Andre Goy, MD, @AndreGoyMD of @JTCancerCenter @HackensackUMC regarding the ZUMA-2 study investigating anti-CD19 CAR… https://t.co/3D4ynHF64R

Dec 16
Daniel Pollyea, MD,@DanPollyea of @CUCancerCenter discusses prognostic factors in acute myeloid leukemia (AML) pati… https://t.co/rzlQEK9pie

Dec 16
Jae H. Park, MD, of @sloan_kettering on the factors associated with improved survival after CD19 CAR-T cell therapy… https://t.co/eYwzIQiW3n